Advancing Antibiotic Use and Preventing Hearing Loss in Babies: Evidence-generation plan for Genedrive MT-RNR1 ID Kit

By Staff Writer

August 14, 2023

NICE has recommended further evidence generation for the Genedrive MT-RNR1 ID Kit, a technology developed to detect a genetic variant that guides antibiotic use and prevents hearing loss in babies.

This plan outlines the gaps in evidence for the technology and the real-world data that needs to be collected for a future NICE review. The responsibility for data collection and analysis lies with the technology developer.

Support for evidence generation will be facilitated by the Office for Life Sciences, pending business case approval. This includes funding for evidence generation consortia, bringing together analytical partners, implementation sites, and developers.

Guidance on commissioning and procurement of the technology will be provided by NHS England, who is also developing a digital health technology policy framework.

After 3 years of evidence generation, the developer should submit the evidence to NICE for review and decision making on routine adoption in the NHS.

Reference url

Recent Posts

NICE health technology evaluations
        

Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives and Addressing Health Inequalities

🌟 Are you ready to embrace a new era in health technology evaluations?

Our latest article dives into the recent updates from NICE regarding the incorporation of patient perspectives and tackling health inequalities in their health technology assessments. By exploring stakeholder feedback and proposed methodologies, we uncover a shift towards more inclusive and transparent evaluations that could reshape market access and reimbursement policies in the UK healthcare system.

Don’t miss out on these vital insights that could impact your understanding of healthcare value! Read the full article [here](https://www.nice.org.uk/process/pmg36/documents/consultation-comments-and-responses).

#SyenzaNews #HealthEconomics #MarketAccess

Canada Drug Agency Plan
          

Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030

🚀 Are you ready to explore the future of healthcare in Canada?

The newly launched **Canada Drug Agency Plan** aims to redefine how we approach drug and health technology decisions, focusing on anticipation, innovation, and transformation to boost health outcomes for all Canadians. This five-year strategic initiative captures essential insights needed for a healthier nation amid evolving pharmaceutical policies.

Curious how this plan could impact the healthcare landscape? Dive into the full article to learn more!

#SyenzaNews #HealthcarePolicy #HealthTech #Innovation

hepatitis C treatment options
       

VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options

🔍 Are you curious about the latest advancements in hepatitis C treatment options?

The groundbreaking VIETNARMS trial reveals that sofosbuvir-daclatasvir offers a comparable efficacy to sofosbuvir-velpatasvir while exploring innovative strategies that could reshape treatment accessibility and affordability. With cure rates exceeding 90%, these findings hold promise for improving outcomes, especially in underserved populations.

Dive into the full article to uncover how these developments could revolutionize hepatitis C care!

#SyenzaNews #globalhealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.